The US Food and Drug Administration has approved the use of AstraZeneca's Nexium (esomeprazole) in children aged one to 11 years for the short-term treatment of gastroesophageal reflux disease for up to eight weeks, helping to address an important unmet need for pediatric patients. The drug received clearance in April 2006 for adolescents 12 to 17 years old for GERD.
The FDA has also approved a new 10mg dose formulation of Nexium for delayed-release oral suspension for use in children one to 11 years old.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze